Cornea

Phase 3 shows epi-on oxygen CXL flattens pediatric keratoconus, improves vision, and stays well tolerated—now commercially available.

An off-the-shelf corneal cell injection targets FECD and bullous keratopathy, aiming to restore vision and ease donor shortages.

QoL areas measured included enjoying relationships/life, overall mood, and time spent thinking of eye pain.

The 3rd Winterthur Ophthalmology Symposium in Winterthur, Switzerland, on 12–13 March 2026 will feature plenary talks, hands-on workshops, satellite sessions, poster presentations, and a gala honoring the Otto Haab Medal.

The clinical study will evaluate a noninvasive corneal strengthening procedure designed to reshape the cornea and correct refractive errors in-office without tissue removal.

FDA clears DifGen’s generic fluorometholone 0.1% eye drop suspension, expanding lower-cost options for anterior eye inflammation and steroid care.

Interventional therapies give patients faster relief and better outcomes

Retina experts unpack MacTel type 2—spot subtle signs, understand anti-VEGF limits, and explore emerging neuroprotective treatments.

FDA feedback backs urcosimod’s Phase 2b/3 plan for neuropathic corneal pain, defining a meaningful pain endpoint in an unmet field.

FDA authorizes compassionate use of urcosimod for neuropathic corneal pain, a condition that causes severe pain and sensitivity of the eyes, face, or head.

Post‑Pfizer mRNA shots show short‑term corneal thickening and lower endothelial cell density, prompting closer monitoring for graft or low‑count patients.

Patients underwent a full ophthalmologic examination that included optical coherence tomography (OCT), OCT angiography, and biometry.

“Remarkable” results were reportedly obtained with hypotony with hydroxypropyl methylcellulose.

An in-depth look at the FDA approvals and clinical milestones that defined 2025 and how they are poised to influence practice patterns moving into 2026.

Retina experts unpack MacTel type 2, why anti-VEGF falls short, and how new cell-based gene therapy fits real-world care.

Real-world insights guide the way to tailored treatment.

Isocyclosporin is a dual inhibitor of transient receptor potential cation channel, mucolipin subfamily, member 2 (TRPML2), and calcineurin.

Tips for optimizing surgical techniques to reduce recurrence and enhance outcomes.

The grading scales were compiled with the goals of achieving conciseness and the ability to provide clear drug-dose-modification recommendations compared with the previous ocular CTCAE scale.